3rdPartyFeeds

SHAREHOLDER ALERT: OMCL NFLX ABMD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / August 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a ... Read More...

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / August 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.” data-reactid=”11″>NEW YORK, NY / ACCESSWIRE / August 13, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Omnicell, Inc. (OMCL)” data-reactid=”12″>Omnicell, Inc. (OMCL)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/omnicell-inc-loss-submission-form?prid=2932&amp;wire=1
Lead Plaintiff Deadline: September 16, 2019
Class Period: October 25, 2018 to July 11, 2019″ data-reactid=”13″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/omnicell-inc-loss-submission-form?prid=2932&wire=1
Lead Plaintiff Deadline: September 16, 2019
Class Period: October 25, 2018 to July 11, 2019

Allegations against OMCL include that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Netflix, Inc. (NFLX)” data-reactid=”15″>Netflix, Inc. (NFLX)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netflix-inc-loss-submission-form?prid=2932&amp;wire=1
Lead Plaintiff Deadline: September 20, 2019
Class Period: April 17, 2019 to July 17, 2019″ data-reactid=”16″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/netflix-inc-loss-submission-form?prid=2932&wire=1
Lead Plaintiff Deadline: September 20, 2019
Class Period: April 17, 2019 to July 17, 2019

Allegations against NFLX include that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Abiomed, Inc. (ABMD)” data-reactid=”18″>Abiomed, Inc. (ABMD)

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/abiomed-inc-loss-submission-form?prid=2932&amp;wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: January 31, 2019 to July 31, 2019″ data-reactid=”19″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/abiomed-inc-loss-submission-form?prid=2932&wire=1
Lead Plaintiff Deadline: October 7, 2019
Class Period: January 31, 2019 to July 31, 2019

Allegations against ABMD include that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.” data-reactid=”21″>To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]” data-reactid=”23″>CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Law Offices of Vincent Wong” data-reactid=”24″>SOURCE: The Law Offices of Vincent Wong

View source version on accesswire.com:
https://www.accesswire.com/555825/SHAREHOLDER-ALERT-OMCL-NFLX-ABMD-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Read More

Add Comment

Click here to post a comment